Gilead Sciences, Inc. (NASDAQ:GILD)  plans to present over 20 research abstracts—spanning both Gilead and its cell therapy unit Kite—at two major medical conferences: the 2025 ASCO Annual Meeting (May ...

Gilead Sciences' Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Squibb over patents relating to CAR-T therapies, overturning a $1.2 billion fine levied ...

Despite the significance of the breakthrough, the recent history of the treatments has been dogged by controversy over pricing, and an ongoing legal battle between Gilead and the US government ...